摘要
目的分析重组甘精胰岛素联合门冬胰岛素治疗2型糖尿病的临床效果。方法入组本院科室2019年1月—2020年1月收治的2型糖尿病患者共70例,随机分组,对照组的患者采取门冬胰岛素联合诺和灵N睡前用药,观察组采取门冬胰岛素注射联合重组甘精胰岛素睡前用药。比较两组血糖达标时间、治疗前后患者空腹血糖、餐后血糖以及糖化血红蛋白、整体疗效、低血糖率。结果观察组血糖达标时间、治疗后患者空腹血糖、餐后血糖以及糖化血红蛋白、整体疗效、低血糖率均优于对照组,P<0.05。结论重组甘精胰岛素联合门冬胰岛素治疗2型糖尿病的临床效果确切,可有效改善患者血糖,减少低血糖发生率。
Objective To analyze the clinical effect of recombinant insulin glargine combined with insulin asparagus in the treatment of type 2 diabetes mellitus.Methods A total of 70 patients with type 2 diabetes treated in the department of our hospital from January 2019 to January 2020 were randomly divided into two groups.The patients in the control group were treated with insulin aspartate combined with novolin N before going to bed.The observation group was treated with insulin injection combined with recombinant glargine insulin before bedtime.The time of reaching the standard of blood glucose,fasting blood glucose,postprandial blood glucose,glycosylated hemoglobin,overall curative effect and hypoglycemia rate were compared between the two groups.Results The time of reaching the standard of blood glucose,fasting blood glucose,postprandial blood glucose,glycosylated hemoglobin,overall curative effect and hypoglycemia rate in the observation group were superior to those in the control group(P<0.05).Conclusion Recombinant insulin glargine combined with insulin asparagus is effective in the treatment of type 2 diabetes,which can effectively improve blood glucose and reduce the incidence of hypoglycemia.
作者
叶伟锋
YE Weifeng(General Practice,Xingning People's Hospital,Xingning Guangdong 514500,China)
出处
《中国卫生标准管理》
2020年第24期101-102,共2页
China Health Standard Management
关键词
重组甘精胰岛素
门冬胰岛素
2型糖尿病
临床效果
低血糖
糖化血红蛋白
recombinant glargine insulin
aspartate insulin
type 2 diabetes mellitus
clinical effect
hypoglycemia
glycosylated hemoglobin
